Medtronic delivered its September 1 earnings and the analyst community has responded with a near-uniform wave of target increases — a post-print reaction that shifts the story from pre-earnings anticipation to whether the stock can close the gap to a freshly upgraded consensus.
The Street's response to the print has been swift and directionally clear. BofA's Bob Hopkins raised his target from $95 to $110 this morning while keeping a Buy rating. Wells Fargo lifted to $104 from $102 on an Overweight. TD Cowen and Needham had already moved ahead of the print — to $110 and $114 respectively — and both maintained Buy after results. Even the more cautious voices moved: Truist lifted its Hold-rated target from $86 to $99, and Stifel nudged its Hold target to $95 from $80. RBC kept an Outperform with a $118 target, the highest on the Street. The consensus mean now stands at $103.44 against a current price of $92.04, implying roughly 12% upside — a wider implied return than the pre-print picture suggested. Truist and Stifel staying at Hold is worth noting; the bullish headline masks a split between firms comfortable adding here and those that want to see further execution before committing.
The bull case leans on Medtronic's portfolio breadth across cardiac, neuromodulation, and surgical categories, and a forward earnings revision score that ranks in the 96th percentile across the universe — meaning analysts are pencilling in meaningful growth. The bear case is more granular: conservative guidance, clinical disappointments in the Intibia System and Symplicity Spyral RDN programmes, and the risk that new launches don't fully offset competitive pressure in mature segments. The EV/EBITDA multiple has drifted lower over the past month to roughly 11.9x, compressing even as the stock rose 7.8% over that stretch — suggesting the market is crediting improving earnings rather than re-rating the multiple. The dividend score ranks in the 84th percentile, a reminder that income investors remain a natural bid for the stock.
Short positioning tells a complementary story — one of bears stepping back rather than adding pressure. Short interest fell roughly 21% on the week to just 1.1% of the free float, continuing a decline that has taken it down nearly 25% over the past month. That drop coincided almost precisely with the earnings date: the short base was sitting around 18 million shares through mid-August and collapsed to 14 million in the days around the September 1 print, suggesting shorts were covering into or immediately after the release. With borrow availability effectively uncapped — the lending pool holds over 1.27 billion shares available — there is no squeeze dynamic at play. Cost to borrow remains negligible at 0.43%. This is simply a low-conviction short base unwinding after an earnings catalyst.
Options positioning is similarly relaxed. The put/call ratio is running at 0.62, essentially in line with its 20-day average of 0.63 and a z-score near zero. There is no hedging overhang from the options market, and no unusual demand for downside protection in the wake of the print. The 52-week PCR range spans from 0.39 to 0.74, and the current reading sits squarely in the middle — neither a complacent nor a cautious extreme.
Among close peers, MDT stands out for its relative weekly performance. ABT fell 6.2% on the week and COO dropped 5.1%. SYK lost nearly 4%, and RMD shed 2.2%. Against that backdrop, MDT's near-flat week — up less than 1% — looks like relative resilience rather than underperformance, particularly for a stock that gained 1.5% on Tuesday alone as the post-earnings analyst notes landed.
The focus now turns to whether the stock can sustain momentum toward the $99–$103 range where the Hold-rated targets cluster, and how the next quarterly print on November 24 compares to a freshly elevated set of Street expectations.
See the live data behind this article on ORTEX.
Open MDT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
